Tvardi Therapeutics announced it will develop TTI-109, an oral STAT3 inhibitor, initially for ulcerative colitis (UC) following successful Phase 1 trials showing immune cell modulation linked to UC. Current UC treatments have low remission rates and safety concerns, while TTI-109 targets a key immune pathway directly, potentially improving outcomes. Tvardi plans to start clinical trials in 2027, pending regulatory approval and funding. A webinar with a leading expert will discuss the drug's potential and UC treatment landscape.
Crescent Biopharma announced its second quarter 2026 financial results, highlighting progress in clinical trials for its cancer therapies, including CR-001, a PD-1 x VEGF bispecific antibody, and ADC candidates CR-002 and CR-003. The company is enrol...
Ferrari reported Q2 2026 net revenues of €1.94 billion, up 8% year-on-year, driven by a richer product mix and increased personalization sales. Operating profit rose 10% to €605 million with a margin of 31.2%, while net profit grew 9% to €463 million...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.58% stake in Gamma Communications PLC as of July 29, 2026. The disclosure, made under Rule 8.3 of the Takeover Code, indicates ownership of 1,414,785 ordinary shares. This filing is a ...
Microsoft's Q2 results reveal robust fundamentals, including 18% year-over-year revenue growth and strong 26% unlevered free cash flow margins despite increased capital expenditures. The company's rapidly expanding order backlog, up 84% year-over-yea...
Cycurion secured its largest contract ever, a $54.6 million, 10-year deal with a top-5 global consulting firm to modernize and secure a state government's Health and Human Services System. The contract will generate over $5 million annually starting ...
